Navellier & Associates Inc. Takes Position in Masimo Co. (NASDAQ:MASI)

Navellier & Associates Inc. purchased a new stake in shares of Masimo Co. (NASDAQ:MASI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,310 shares of the medical equipment provider’s stock, valued at approximately $1,043,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MASI. Allspring Global Investments Holdings LLC boosted its holdings in shares of Masimo by 5,340.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock valued at $319,000 after acquiring an additional 2,350 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of Masimo by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock valued at $685,000 after acquiring an additional 345 shares during the period. SteelPeak Wealth LLC acquired a new position in shares of Masimo during the third quarter valued at $570,000. Roubaix Capital LLC lifted its holdings in Masimo by 37.0% in the third quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock worth $4,539,000 after purchasing an additional 9,202 shares during the period. Finally, Malaga Cove Capital LLC acquired a new stake in Masimo in the third quarter worth about $401,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

Shares of NASDAQ MASI opened at $169.96 on Friday. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $184.51. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $9.10 billion, a price-to-earnings ratio of 117.21 and a beta of 1.02. The firm has a 50-day moving average of $172.78 and a two-hundred day moving average of $152.03.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Piper Sandler upped their price objective on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Raymond James upped their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company upped their price objective on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and a consensus price target of $191.40.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.